Companies
-
Pharma’s AI optimism clashes with payer mistrust
- Fri Jul 24
PBAC chair likens the use of AI to giving the keys to a Ferrari to a 15-year-old and hoping they don’t kill themself. Will pharma and payers ever agree on AI?
Read more -
LSDP loses another ultra-rare therapy
- Wed Jul 22
Government moves to drain the high-cost drug scheme for ultra-rare conditions continues as another medicine migrates to the PBS.
Read more -
AstraZeneca ‘green’ inhaler a breath of fresh air
- Wed Jul 22
Using a next-gen propellant, Breztri Aerosphere is the first respiratory inhaler approved for use in Australia with low environmental impact.
Read more -
PBAC ups fast-track offers and price cuts
- Mon Jul 20
Of PBAC’s March recommendations, just four were deemed worthy of a funding fast track, but it seems not all sponsors are happy with the deal.
Read more -
Novo calls for business tax incentive
- Mon Jul 20
As the government struggles to fund GLP-1s for obesity, Novo says it should use tax incentives to get employers to pick up the tab.
Read more -
Novartis names familiar face as Country President
- Fri Jul 17
One of Australia’s most respected and recognisable pharma leaders will return to the industry to lead the Swiss pharma’s ANZ business.
Read more -
Leaders move in at Astellas, out at J&J, up at AZ
- Fri Jul 17
Astellas’ new head of sales moves over from Bayer as J&J’s medical affairs head for its oncology products says farewell, for now.
Read more -
Lilly proposes sweet deal to fund obesity
- Wed Jul 15
Eli Lilly calls for a tax on sugar drinks as part of a ‘time-limited investment’ to fund implementation of the national obesity strategy.
Read more